On Nov. 24, 2022, researchers Kanta Horie and Chihiro Sato at the Tracy Family SILQ Center at Washington University School of Medicine in St. Louis announced that their team had discovered a biomarker for a rare, deadly brain disease known as corticobasal degeneration (CBD). The biomarker could accelerate efforts to develop treatments for CBD.